Drug Development

Novel aryl semicarbazone has potent antituberculous activity

Published in TB and Outbreaks Week, September 21st, 2004

A novel aryl semicarbazone derivative has demonstrated potent antituberculous activity in vitro.

While "screening new drugs for tuberculosis," scientists in India "identified N1-(4-acetamido phenyl)-N4-(2-nitro benzylidene) semicarbazone (1b)."

This agent strongly "inhibited in vitro Mycobacterium tuberculosis H₃₇ Rv," with "100% inhibition at 1.56 mcg/mL," reported D. Sriram and colleagues working at the Birla Institute of Technology and Science in Rajasthan.

"This paper is first of its kind in which aryl semicarbazones are reported to possess antimycobacterial potency greater than p-aminosalicylic acid,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2004-09-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry